Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company. It has factories in in nine countries. More than 48,000 people work for the company. Nordisk Insulinlaboratorium was started in 1923 by the Danish Nobel laureate August Krogh, pharmacist August Kongsted and scientist Hans Christian Hagedorn. It produced insulin. In 1989 it merged with Novo Industri.[1] 77% of Novo’s voting rights and 28.1% of its shares is owned by the Novo Nordisk Foundation.
It was Europe’s most valuable company in 2023 and dominates the Danish economy. In September 2023 it was worth $421 billion. It plans to buy Inversago Pharma. The Wegovy weight-loss drug has been very successful.[2] It can cut the risk of heart attacks by 20% in overweight or obese patients with cardiovascular disease. It is expected to sell $7.3 billion in 2024. Ozempic, an injectable form of Semaglutide, is used to treat diabetes. It is expected to sell $16.5 billion in 2024.
Lars Fruergaard Jørgensen is the chief executive.[3]
It specialises in diabetes care medications and devices. It also does hemostasis management, growth hormone therapy and hormone replacement therapy.[4]
References[change | change source]
- ↑ "Our History". web.archive.org. 2019-07-08. Archived from the original on 2019-07-08. Retrieved 2023-03-08.
- ↑ Kuchler, Hannah (2023-09-01). "Novo Nordisk briefly eclipses LVMH as Europe's most valuable company". Financial Times. Retrieved 2023-09-02.
- ↑ "FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk". www.ft.com. Retrieved 2023-12-19.
- ↑ "Novo Nordisk sees slower 2020 growth with US insulin prices pressured". CNBC. Retrieved 2023-03-08.